Deadline for manuscript submissions: 30 August 2022Print Special Issue Flyer (5)
Institut d'analyse génomique-Imagenome, Labosud, Montpellier, France
Interests: Cancer biomarkers
Prostate cancer is the most common cancer in men. The median age of diagnosis is just before the age of 70, and the five-year survival rate is 94%. Prostate cancer generally presents a good prognosis, and it can, thus, be discussed with the patient of whether to avoid a diagnostic biopsy in certain clinical situations of suspected prostate cancer. In the case of a positive biopsy, there are different options to consider, such as active surveillance, watchful waiting, or the initiation of local treatment. To guide the patient’s choice between these options, it is necessary to determine the prognosis of the disease and define the stage of the cancer. Prostate cancer staging is based on the tumor extent using TNM categories, the PSA level and the Gleason score (Grade group). Risk groups, based on PSA, digital rectal examination, and biopsy, from very low to very high are used to determine treatment options, but they are not perfect indicators of the risk. There are ongoing efforts to develop new biomarkers, based on blood or tissue testing, that can aid clinicians in determining which cancers are supposed to be aggressive and need specific treatment.
Biomarkers could also be used to improve the early detection of prostate cancer, to avoid negative biopsies and other diagnoses, to avoid repeated biopsies, and to reduce the number of different diagnostic procedures (MRI, biopsy, other biomarkers, etc.). Recently, targeted therapies have been developed to treat metastatic prostate cancers, and biomarkers predictive of response or resistance to these treatments could be used for the management of these patients. There is currently a need to technically and clinically validate these biomarkers. This Special Issue will focus on the evaluation of the use of new biomarkers in different clinical settings to improve prostate cancer management.
biology, prostate, cancer, biomarkers, prognostic, prediction, protein, molecular biomarkers, oncogenetics
Submissions will be accepted on a rolling basis and reviewed by experts in the field. Rapid peer review and prompt editorial decisions will ensure that quality manuscripts are published on time. The manuscript has not already been published or submitted elsewhere (except conference proceedings papers). If similar work has been published or submitted elsewhere, you must provide a copy of the submitted manuscript. You may not submit your manuscript elsewhere while it is under consideration at the Journal of Men's Health. All manuscripts undergo thorough double-blind peer-review. To check the suitability of the special issue for publishing your manuscript, please read the journal's aims and scope and read or download the guide for authors. You may also send a brief abstract of your work (about 100 words) to the Editorial Office at firstname.lastname@example.org. A guide for authors and other relevant information for manuscript submission is available on the Instructions for Authors page.
Academic Writing and English Language Editing Services
Authors who feel that their manuscript may benefit from additional academic writing or language editing support before submission are strongly encouraged to use academic editing services.
Article Processing Charges (APC)
All manuscripts submitted to the Journal of Men's Health are assessed according to the journal standard editorial criteria. If accepted for publication, an Article Processing Charge of 900 USD applies.
The journal typically offers a 30% discount to submissions with good quality invited by the Editor-in-Chief, Guest Editor (GE) and Editorial Board Member.
Type of Articles: Original Research, Review, Mini-Review, Systematic Review, Short Communication, Case Report, Letter to the Editor, Commentary, Rapid Report, Meeting Report, News and Views
Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.
Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.
CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.
Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.